Led by $1.07bn asset transaction with Lumenis, Israel’s medical devices industry saw a rise of 57.38% in overall deal activity during Q1 2021, when compared with the last four-quarter average, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 24 deals worth $1.42bn were announced in Q1 2021, compared with the last four-quarter average of 15.25 deals.
venture financing was the leading category in the quarter with 15 deals which accounted for 62.5% of all deals.
In second place was M&A with five deals, followed by private equity with four transactions, respectively accounting for 20.8% and 16.7% of overall deal activity in the Israel’s medical devices industry during the quarter.
In terms of value of deals, M&A was the leading deal category in Israel’s medical devices industry with total deals worth $1.13bn, while venture financing and private equity deals totalled $196.5m and $88.4m, respectively.
Israel medical devices industry deals in Q1 2021: Top deals
The top five medical devices industry deals accounted for 88.9% of the overall value during Q1 2021.
The combined value of the top five medical devices deals stood at $1.26bn, against the overall value of $1.42bn recorded for the quarter.
The top five medical devices industry deals of Q1 2021 tracked by GlobalData were:
1) Boston Scientific ’s $1.07bn asset transaction with Lumenis
2) The $70m private equity deal with DarioHealth by Driehaus Capital Management , Farallon Capital Management , More Provident Funds , Nantahala Capital Management, Perceptive Advisors , Phoenix Insurance and Pura Vida Investments
5) DarioHealth ’s acquisition of Upright Technologies for $31m.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.